RSS Feed Print
Brain Cap 40 Hz Gamma Induction, Boston MA
Posted: Sunday, November 10, 2019 9:24 PM
Joined: 2/17/2019
Posts: 380

Device: Transcranial Alternating Current Stimulation (tACS)

tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
Other Name: Non-invasive Brain Stimulation
United States, Massachusetts Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Luke Pezanko    617-667-0386    Contact: Molly O'Reilly    617-667-0249    Principal Investigator: Emiliano Santarnecchi, PhD         

Posted: Wednesday, November 13, 2019 11:13 AM
Joined: 2/17/2019
Posts: 380

This is the Cell Phone Wave Cap that Steve3D posted about.


A very similar study is being run in Aurora Colorado

  University of Colorado AMC
Aurora, Colorado, United States


Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance


Brief Summary:
Loss of slow wave sleep (SWS) is common in mild cognitive impairment (MCI) and Alzheimer's disease, and is thought to worsen thinking, memory and brain degeneration.
  Initial studies suggest that correction of sleep deterioration may slow the progression of brain damage in mild cognitive impairment, and might be able to stop the development of Alzheimer's disease. 
 Transcranial alternating current stimulation (tACS) uses electrodes to deliver very small amounts of electricity through the brain, with direct effects on brain cell function. 
 Transcranial electric stimulation has been demonstrated to enhance slow wave sleep and to improve memory when applied during sleep in healthy adults.
 The purpose of this research is to investigate tACS to modulate sleep, thinking/memory, mood, and quality of life among normal healthy adults, older adults, as well as individuals with MCI.


Study Type  : Interventional  (Clinical Trial)

  Estimated Enrollment : 145 participants

 Allocation: Randomized Intervention

 Model: Crossover Assignment

 Masking: Triple (Participant, Care Provider, Outcomes Assessor)

  Primary Purpose: Other Official Title: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance

 Actual Study Start Date  : March 7, 2018

  Estimated Primary Completion Date  : December 2019

  Estimated Study Completion Date  : December 2019

Posted: Wednesday, November 13, 2019 11:20 AM
Joined: 2/17/2019
Posts: 380

If you still think stimulating the brain via TACS (Transcranial Alternating Current Stimulation) is a sham, don't look at this page of 29 studies on it.

Wait, wait, 2 of these are about how coffee stimulates the brain, so correction, 27 current studies of TACS, which is non-invasive, so much so that sometimes ITS A HAT you wear for 2 hours a day.

Not yet recruiting

NEWLUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina, United States


RecruitingNon-Invasive Brain Stimulation and Delirium
  • University of Iowa
    Iowa City, Iowa, United States

Posted: Sunday, November 17, 2019 6:37 PM
Joined: 8/13/2019
Posts: 12


Posted: Saturday, February 8, 2020 10:59 PM
Joined: 2/17/2019
Posts: 380

TEMT induced clinically important and statistically significant improvements in ADAS-cog, as well as in the Rey AVLT. 



Small aggregates (oligomers) of the toxic proteins amyloid-β (Aβ) and phospho-tau (p-tau) are essential contributors to Alzheimer’s disease (AD). In mouse models for AD or human AD brain extracts, Transcranial Electromagnetic Treatment (TEMT) disaggregates both Aβ and p-tau oligomers, and induces brain mitochondrial enhancement. These apparent “disease-modifying” actions of TEMT both prevent and reverse memory impairment in AD transgenic mice.


To evaluate the safety and initial clinical efficacy of TEMT against AD, a comprehensive open-label clinical trial was performed.


Eight mild/moderate AD patients were treated with TEMT in-home by their caregivers for 2 months utilizing a unique head device. TEMT was given for two 1-hour periods each day, with subjects primarily evaluated at baseline, end-of-treatment, and 2 weeks following treatment completion.


No deleterious behavioral effects, discomfort, or physiologic changes resulted from 2 months of TEMT, as well as no evidence of tumor or microhemorrhage induction.

TEMT induced clinically important and statistically significant improvements in ADAS-cog, as well as in the Rey AVLT. 

TEMT also produced increases in cerebrospinal fluid (CSF) levels of soluble Aβ1-40 and Aβ1-42, cognition-related changes in CSF oligomeric Aβ, a decreased CSF p-tau/Aβ1-42 ratio, and reduced levels of oligomeric Aβ in plasma. 

Pre- versus post-treatment FDG-PET brain scans revealed stable cerebral glucose utilization, with several subjects exhibiting enhanced glucose utilization. 

Evaluation of diffusion tensor imaging (fractional anisotropy) scans in individual subjects provided support for TEMT-induced increases in functional connectivity within the cognitively-important cingulate cortex/cingulum.


TEMT administration to AD subjects appears to be safe, while providing cognitive enhancement, changes to CSF/blood AD markers, and evidence of stable/enhanced brain connectivity.